November 2023 FDA Recall Ondansetron Hydrochloride by Baxter Healthcare Corporation
D-0146-2024 - Failed pH Specifications

This Class II drug recall was voluntarily initiated by Baxter Healthcare Corporation on November 14, 2023 for the product Ondansetron Hydrochloride. The FDA reported the reason for recall as failed ph specifications. The product was distributed Nationwide and the recall is currently completed.

Recall Number: D-0146-2024

Reason for Recall
Failed pH Specifications
Initiated
11-14-2023
Reported
12-13-2023
Quantity
6,022,675 vials

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Baxter Healthcare Corporation
Nationwide in the USA
Ondansetron Injection, USP, 4 mg/2 mL (2 mg/mL), 2 mL per vial, Rx only, Manufactured for: Baxter Healthcare Corporation, Deerfield, IL 60015 USA. Manufactured by: Baxter Pharmaceuticals India Private Ltd, Ahmedabad 382213, India. NDC 36000-012-25

Batch or Lot Expiration Information

Lot# A0E0959A, A0E0961A, A0E1015A, A0E1020A, Exp. Date 30-Nov-23; A0F0016A, Exp. Date 31-Dec-23; A0F0260A, A0F0261A, A0F0262A, Exp. Date 29-Feb-24; A0F0414A, A0F0415A, A0F0416A, A0F0417A, A0F0418A, Exp. Date 30-Apr-24; A0F0503A, Exp. Date 31-May-24, A0F0533A, A0F0534A, A0F0535A, A0F0536A, A0F0537A, A0F0540A, A0F0541A, Exp. Date 30-Jun-24; A0F0573A, A0F0574A, A0F0575A, A0F0592A, Exp. Date 31-Jul-24; A0F0596A, A0F0599A, Exp. Date 31-Aug-24 ; A0F0676A, 31-Oct-24.